Use of linezolid, an oxazolidinone, in the treatment of multidrug- resistant gram-positive bacterial infections

Clinical Infectious Diseases

Volumn 30, Issue 1, 2000, Pages 146-151

  Chien, Jason W ^a   Kucia, Michelle L ^a   Salata, Robert A ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALATROFLOXACIN; AMIKACIN; AMPHOTERICIN B; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLOTRIMAZOLE; COTRIMOXAZOLE; ERYTHROMYCIN; FLUCONAZOLE; GANCICLOVIR; GENTAMICIN; IMIPENEM; LINEZOLID; MEROPENEM; METRONIDAZOLE; OXAZOLIDINONE DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ABSCESS DRAINAGE; ADULT; ARTICLE; BACTERIAL INFECTION; CANCER; CLINICAL ARTICLE; ENDOCARDITIS; ENTEROCOCCUS; EPIDURAL ABSCESS; FEMALE; GRAM POSITIVE BACTERIUM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LEUKOPENIA; LIVER TRANSPLANTATION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; MYCOSIS; NAUSEA; PAROTITIS; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; SURGERY;

ACETAMIDES; ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; ENTEROCOCCUS; EPIDURAL ABSCESS; FEMALE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OXAZOLES; OXAZOLIDINONES; PAROTITIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 0033973539     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313597     Document Type: Article

References (26)

1. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991; 91:86S-9S.
2. National Nosocomial Infections Surveillance (NNIS) System report, data summary from October 1986 April 1998, issued June 1998. Am J Infect Control 1998;26:522-33.
3. Jones RN. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med 1996; 100:3S-12S.
4. Martone WJ. Spread of vancomycin-resistant enterococci: why did it happen in the United States? Infect Control Hosp Epidemiol 1998; 19:539-45.
5. Bonten MJ, Hayden MK, Nathan C, et al. Epidemiology of colonisation of patients and environment with vancomycin-resistant enterococci. Lancet 1996; 348:1615-9.
6. Papanicolaou GA, Meyers BR, Meyers J, et al. Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: risk factors for acquisition and mortality. Clin Infect Dis 1996; 23:760-6.
7. Linden PK, Pasculle AW, Manez R, et al. Differences in outcomes for patients with bacteremia due to vancomycin- resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis 1996; 22:663-70.
8. Mainous MR, Lipsett PA, O'Brien M. Enterococcal bacteremia in the surgical intensive care unit: does vancomycin resistance affect mortality? The Johns Hopkins SICU Study Group. Arch Surg 1997; 132:76-81.
9. Stroud L, Edwards J, Danzing L, Culver D, Gaynes R. Risk factors for mortality associated with enterococcal bloodstream infections. Infect Control Hosp Epidemiol 1996; 17:576-80.
10. Tornieporth NG, Roberts RB, John J, Hafner A, Riley LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996; 23:767-72.
11. Wells CL, Juni BA, Cameron SB, et al. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis 1995; 21:45-50.
12. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995; 172:993-1000.
13. Lautenbach E, Schuster MG, Bilker WB, Brennan PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998; 27:1259-65.
14. Bostic GD, Perri MB, Thal LA, Zervos MJ. Comparative in vitro and bactericidal activity of oxazolidinone antibiotics against multidrug-resistant enterococci. Diagn Microbiol Infect Dis 1998; 30:109-12.
15. Chia JK, Nakata MM, Park SS, Lewis RP, McKee B. Use of bacitracin therapy for infection due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 1995; 21:1520.
16. Linden PK. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med 1998; 104:24S-33S.
17. Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, Schentag JJ. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis 1998; 31:437-51.
18. Linden PK, Pasculle AW, McDevitt D, Kramer DJ. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. J Antimicrob Chemother 1997; 39(Suppl A):145-51.
19. Wood CA, Blumberg EA, Fuchs AE, Molavi A, Mandler HD. Quinupristin/dalfopristin (Synercid) treatment of infections caused by vancomycin-resistant Enterococcus faecium (VREF) [abstract 606]. Clin Infect Dis 1998; 27:1035.
20. Wood CA, Blumberg EA, Fuchs AE, et al. Emergence of resistance to quinupristin/dalfopristin (Synercid) during treatment of infections caused by vancomycin-resistant Enterococcus faecium (VREF) [abstract 607]. Clin Infect Dis 1998; 27:1035.
21. Mandler HD, Blumberg EA, Fuchs AE, Molavi A, Wood CA. Arthralgias and myalgias associated with quinupristin/dalfopristin (Synercid) treatment of infections caused by vancomycin-resistant Enterococcus faecium (VREF) [abstract 608]. Clin Infect Dis 1998; 27:1035.
22. Chow JW, Donahedian SM, Zervos MJ. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect Dis 1997; 24:90-1.
23. Dresser LD, Rybak MJ. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 1998; 18:456-62.
24. Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 1998; 42:721-4.
25. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service [see comments]. Am J Med 1994; 96:200-9.
26. Birmingham MC, Zimmer GS, Hafkin B, et al. Outcomes with linezolid from an ongoing compassionate use trial of patients with significant, resistant, gram positive infections. Poster presentation at the International Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 1999.